The Status Of Lipid-modifying Therapy For Patients With Type 2diabetes In Some Tertiary Hospitals Of Ningbo:A Cross-sectional Study

Background: Diabetes clearly is a global public health problem and the epidemic situation of diabetes in China is particularly severe which currently has the highest number of patients in the world.The serious harm of diabetes is the occurrence of its complications and macrovascular disease is common in type 2 diabetes.Among them,atherosclerotic cardiovascular disease(ASCVD)is the leading cause of death and disability in patients with diabetes mellitus.It brings heavy economic and medical pressure to patients and society.Abnormal lipid metabolism promotes the development of atherosclerosis in diabetic patients,which is an important pathological basis of ASCVD.At present,a large amount of evidence at home and abroad has proved that active lipid-lowering therapy for patients with diabetes is very beneficial.Aims:We conducted this cross-sectional study of the status of lipid-modifying therapy for patients with type 2 diabetes in some tertiary hospitals of Ningbo(including Hwa Mei Hospital,University of Chinese Academy of Sciencesto and Nningbo University School of Medicine Affiliated Hospital)reveal the lipid status in patients with type 2 diabetes in Ningbo.Methods:We analyzed clinical data of patients with type 2 diabetes who were treated in tertiary hospitals of Ningbo in 2018.Results: Of the 1,592 T2 DM patients included in the study,364 patients were receiving lipidlowering therapy.The overall rate of lipid-lowering drugs was 22.86%,and the lipid-compliance rate was 60.18%.Age,the duration of T2 DM,history of ASCVD,Hb A1 c,BMI,and whether lipid-lowering therapy is being performed are associated with blood lipid levels in patients with type 2 diabetes.Adjustments for gender,blood pressure compliance,family history of ASCVD,smoking and drinking,age,the duration of T2 DM,history of ASCVD,Hb A1 c,BMI,whether lipid-lowering therapy and lipid-compliance rate remained statistically significant.Patients who received lipid-lowering therapy had a lipid-compliance rate of 2.642 times that of patients who did not receive lipid-lowering therapy(OR2.642,95%CI(2.016-3.462)).The rate of lipidcompliance in patients with ASCVD is much lower than that in patients without ASCVD(OR0.507,95%CI(0.385-0.667)).At the same time,age and the duration of T2 DM were positively related to blood lipid levels,while BMI and Hb A1 c were negatively related to blood lipid levels.Conclusions:Our results show that the use of lipid-lowering drugs and blood lipid compliance rates in patients with type 2 diabetes in Ningbo were relatively low.Receiving lipid-lowering therapy,strict control of BMI and blood glucose can help improve blood lipid levels in patients with T2 DM.